# Malaysia Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Malaysia HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Malaysia (MYS)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $1.5B
- Products: 47
- Buyer markets: 28
- Average CAGR: +19.4%
- Global sector size: $720.3B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $302.0B | $11.4M | $114.3B | +3.5% | 20 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $142.1B | $810.4K | $54.1B | +89.6% | 10 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $27.6B | $198.7K | $22.9B | -9.5% | 6 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $26.4B | $2.4M | $15.0B | +29.6% | 5 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.1B | $270.5M | $14.5B | +36.3% | 6 | +1.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.8B | $62.7K | $11.7B | -7.8% | 2 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $13.4B | $357.4M | $11.6B | +32.5% | 5 | +2.4% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $19.3B | $2.7M | $10.5B | +36.9% | 5 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $6.8B | $35.7K | $9.6B | -14.0% | 2 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $11.9B | $1.2K | $7.4B | -24.5% | 2 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $5.0B | $3.8M | $7.4B | +37.1% | 3 | +0.1% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $140.3 | $6.7B | -15.1% | 1 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $2.1M | $6.3B | +22.6% | 3 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $7.8B | $59.0K | $6.3B | -4.2% | 2 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $8.4M | $5.9B | +19.3% | 2 | +0.1% |
| HS 290243 - Cyclic hydrocarbons: p-xylene | $8.5B | $279.0M | $5.8B | +27.7% | 1 | +3.3% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $5.0B | $30.2M | $5.6B | +40.7% | 3 | +0.5% |
| HS 290110 - Acyclic hydrocarbons: saturated | $2.9B | $25.5K | $5.1B | -6.1% | 2 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $6.6B | $79.9M | $4.8B | +15.4% | 3 | +1.2% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $3.8B | $4.9K | $4.6B | -7.0% | 2 | +0.0% |
| HS 282200 - Cobalt oxides and hydroxides: commercial cobalt oxides | $2.4B | $14.1K | $4.6B | -2.9% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $6.6B | $126.5K | $4.1B | -0.1% | 2 | +0.0% |
| HS 283691 - Carbonates: lithium carbonate | $2.5B | $1.1 | $3.8B | -99.4% | 1 | +0.0% |
| HS 290220 - Cyclic hydrocarbons: benzene | $4.1B | $200.3M | $3.1B | +37.9% | 1 | +4.9% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $2.3B | $12.9K | $3.1B | +19.0% | 1 | +0.0% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $348.8K | $2.4B | +21.8% | 1 | +0.0% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $49.8K | $2.4B | +65.8% | 1 | +0.0% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $51.3M | $2.3B | +31.6% | 1 | +2.8% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $50.0M | $2.2B | +40.0% | 1 | +1.5% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $63.8K | $2.1B | +0.4% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $71.5K | $2.0B | +8.1% | 1 | +0.0% |
| HS 293299 - Heterocyclic compounds: with oxygen hetero-atom(s) only, no lactones or unfused furan rings (hydrogenated or not) in the structure, other than isosafrole, 1-(1,3-benzodiaxol-5-yl) propan-2-one, piperonal, safrole, tetrahydrocannabinols (all isomers) | $2.4B | $39.2K | $2.0B | +14.8% | 1 | +0.0% |
| HS 290122 - Acyclic hydrocarbons: unsaturated, propene (propylene) | $1.6B | $18.9M | $1.8B | +31.8% | 1 | +1.2% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $2.2B | $3.0K | $1.8B | -11.5% | 1 | +0.0% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $4.5M | $1.7B | +15.1% | 1 | +0.2% |
| HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $6.3M | $1.7B | +32.8% | 1 | +0.3% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $129.7M | $1.7B | +15.4% | 1 | +9.6% |
| HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $4.9B | $2.4K | $1.7B | -8.8% | 1 | +0.0% |
| HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $627.1 | $1.7B | -12.9% | 1 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.9B | $650.3 | $1.5B | +7.0% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $509.4 | $1.4B | -30.9% | 1 | +0.0% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $3.3B | $0.5 | $1.4B | -24.6% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $4.8K | $1.4B | +5.8% | 1 | +0.0% |
| HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $36.8M | $1.3B | +77.5% | 1 | +2.3% |
| HS 293722 - Steroidal hormones, their derivatives and structural analogues: halogenated derivatives of corticosteroidal hormones | $1.5B | $449.0K | $1.3B | +54.6% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $8.5K | $1.2B | -5.4% | 1 | +0.0% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $2.2B | $59.7 | $1.2B | +16.3% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $102.5B calculated opportunity across 21 products.
- China (CHN): $62.4B calculated opportunity across 21 products.
- Switzerland, Liechtenstein (CHE): $35.1B calculated opportunity across 4 products.
- Germany (DEU): $34.3B calculated opportunity across 11 products.
- Belgium (BEL): $25.0B calculated opportunity across 4 products.
- Netherlands (NLD): $14.3B calculated opportunity across 4 products.
- Canada (CAN): $11.2B calculated opportunity across 6 products.
- United Kingdom (GBR): $11.1B calculated opportunity across 5 products.
- Italy (ITA): $9.8B calculated opportunity across 2 products.
- Slovenia (SVN): $9.7B calculated opportunity across 1 products.
- Japan (JPN): $9.6B calculated opportunity across 3 products.
- Mexico (MEX): $9.0B calculated opportunity across 4 products.

## Growth stars

- HS 300215: +89.6% average CAGR, $54.1B calculated opportunity.
- HS 291736: +77.5% average CAGR, $1.3B calculated opportunity.
- HS 285390: +65.8% average CAGR, $2.4B calculated opportunity.
- HS 293722: +54.6% average CAGR, $1.3B calculated opportunity.
- HS 290919: +40.7% average CAGR, $5.6B calculated opportunity.
- HS 290531: +40.0% average CAGR, $2.2B calculated opportunity.
- HS 290220: +37.9% average CAGR, $3.1B calculated opportunity.
- HS 284190: +37.1% average CAGR, $7.4B calculated opportunity.
- HS 300439: +36.9% average CAGR, $10.5B calculated opportunity.
- HS 382499: +36.3% average CAGR, $14.5B calculated opportunity.

## Diversification opportunities

- HS 300490: 20 buyer markets, $114.3B calculated opportunity.
- HS 300215: 10 buyer markets, $54.1B calculated opportunity.
- HS 300220: 6 buyer markets, $22.9B calculated opportunity.
- HS 382499: 6 buyer markets, $14.5B calculated opportunity.
- HS 300212: 5 buyer markets, $15.0B calculated opportunity.
- HS 382600: 5 buyer markets, $11.6B calculated opportunity.
- HS 300439: 5 buyer markets, $10.5B calculated opportunity.
- HS 284190: 3 buyer markets, $7.4B calculated opportunity.
- HS 382200: 3 buyer markets, $6.3B calculated opportunity.
- HS 290919: 3 buyer markets, $5.6B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.